628-64-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Ethoxyethyl chloroformate is used as a reagent in the synthesis of various pharmaceutical compounds. Its unique chemical properties make it a valuable component in the production of certain medications.
Used in Pesticide Industry:
In the pesticide industry, 2-Ethoxyethyl chloroformate is utilized as a reagent for the synthesis of specific pesticides. Its role in the production process contributes to the development of effective pest control agents.
Used in Organic Synthesis:
2-Ethoxyethyl chloroformate is employed as a versatile reagent in organic synthesis, enabling the creation of a wide range of chemical compounds for various applications. Its unique properties facilitate specific chemical reactions that are essential in the synthesis process.

InChI:InChI=1/C5H9ClO3/c1-2-8-3-4-9-5(6)7/h2-4H2,1H3

Upstream product

• 110-80-5 2-ethoxy-ethanol 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 75-44-5 phosgene 

Downstream Products

• 83264-11-3 (4-hydroxy-phenyl)-carbamic acid-(2-ethoxy-ethyl ester) 
• 52373-74-7 di-(2-ethoxyethyl)peroxydicarbonate 
• 83264-02-2 (4-Oxiranylmethoxy-phenyl)-carbamic acid 2-ethoxy-ethyl ester 
• 83263-69-8 [4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-carbamic acid 2-ethoxy-ethyl ester 
• 35266-28-5 C₁₂H₁₅N₃O₅S 

Relevant academic research and scientific papers

CONTROLLED RELEASE PREPARATION

A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE

Granule, fine particle or tablet of excellent leaching property, comprising a drug active ingredient in high content realized by forming a layer containing drug active ingredient on core particles through a combination of a method of dispersing and adhering an active ingredient while spraying or adding a binder with a method of spraying or adding a solution or suspension wherein an active ingredient and a binder are contained so as to effect adhesion. Further, there are provided a drug composition containing such a granule, fine particle or tablet and a process for producing the same.

CONTROLLED RELEASE COMPOSITION

The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate,2) a release-controlled part B capable of controlling release of the active ingredient to occur at a predetermined rate lower than the release rate of the release-controlled part A, and where necessary, 3) a release-controlled part C capable of controlling release of the active ingredient to occur at a predetermined rate faster than the release rate of the release-controlled part B, wherein the release of the active ingredient from the release-controlled part B precedes the release of the active ingredient from the release-controlled part A (when release-controlled part C is contained, the release of the active ingredient from the release-controlled part C precedes the release of the active ingredient from the release-controlled part B).

PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS

An imidazole compound represented by the formula (I), a salt thereof and a compound of the formula (V), which is one of the intermediates thereof. wherein each symbol is as defined in the present specification. The compound of the present invention shows a superior anti-ulcer activity, a gastric acid secretion inhibitory action, a mucosa-protecting action, an anti-Helicobacter pylori action and the like. Since it shows low toxicity, the compound is useful as a pharmaceutical product.

KINETICS AND MECHANISM OF PHOSGENATION OF ALIPHATIC ALCOHOLS. IV. EFFECT OF HYDROGEN CHLORIDE ON THE REACTION RATE

The reaction of phosgene with alcohols is inhibited by hydrogen chloride.Here, as shown for the model methanolysis of methyl chloroformate, the halide ions have practically no effect on the reaction rate.The inhibition is due to the formation of associates, which do not possess nucleophilic characteristics between the alcohol and the hydrogen chloride.In proton-inert solvents at low temperatures the reaction only goes to the extent of a third on account of the formation of a stable unreactive 2:1 associate of the alcohol with hydrogen chloride.